QIAGEN/Pfizer to Develop Diagnostic for Lung Cancer

September 2011
Worldwide Biotech;Sep2011, Vol. 23 Issue 9, p1
Trade Publication
The article reports on the partnership deal signed by biotechnology firms Qiagen and Pfizer to develop a companion molecular diagnostic test for non-small cell lung cancer (NSCLC). The test will be used to analyze the effectiveness of Pfizer's investigational compound, dacomitinib, the oral inhibitor of human epidermal growth factor receptor as a target for the treatment of NSCLC. The companion diagnostic of Qiagen will effectively determine mutations of the Kras gene found in human cancers.


Related Articles

  • Optimizing tissue sampling for the diagnosis, subtyping, and molecular analysis of lung cancer. Ofiara, Linda Marie; Beaudoin, Stephane; Gonzalez, Anne Valerie; Navasakulpong, Asma // Frontiers in Oncology;Sep2014, Vol. 4, p1 

    Lung cancer has entered the era of personalized therapy with histologic subclassification and the presence of molecular biomarkers becoming increasingly important in therapeutic algorithms. At the same time, biopsy specimens are becoming increasingly smaller as diagnostic algorithms seek to...

  • Targeted therapy for lung cancer: Implications for pharmacy practice.  // American Journal of Health-System Pharmacy;12/15/2003, Vol. 60 Issue 24, pS22 

    The article presents an overview of the continuing education (CE) program on the topic "Targeted therapy for lung cancer: Implications for pharmacy practice." Learning objectives of the course include summary of targeted therapies of lung cancer, description of efficacy, safety and symptom...

  • Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report. YUE FENG WANG; XIANHONG XIANG; XIAOJUAN PEI; SHUHUA LI; CUILAN TANG; LIANTANG WANG; ZUN-FU KE // Oncology Letters;2014, Vol. 8 Issue 3, p1039 

    Lung cancer is the leading cause of mortality among malignant diseases in humans worldwide. During the last decade, molecular targeted therapies for non-small cell lung cancer using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including...

  • Translational research.  // Annals of Oncology;2016 Supplement, Vol. 27, pix179 

    No abstract available.

  • The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization. Tembuyser, Lien; Tack, Véronique; Zwaenepoel, Karen; Pauwels, Patrick; Miller, Keith; Bubendorf, Lukas; Kerr, Keith; Schuuring, Ed; Thunnissen, Erik; Dequeker, Elisabeth M. C. // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Background and Purpose: Molecular profiling should be performed on all advanced non-small cell lung cancer with non-squamous histology to allow treatment selection. Currently, this should include EGFR mutation testing and testing for ALK rearrangements. ROS1 is another emerging target. ALK...

  • Recomendaciones para la determinación de las mutaciones del gen EGFR en el carcinoma de pulmón no microcítico. García-Foncillas, Jesús; Garrido, Pilar; Gómez, Javier; Palacios, José; Tarón, Miquel // Revista Española de Patología;ene-mar2011, Vol. 44 Issue 1, p17 

    Multiple biological studies have demonstrated the important role of the signalling pathway mediated by the epidermal growth factor receptor (EGFR) in the pathogenesis of many lung cancers. In the last decade, several molecular, clinical and pathological findings have demonstrated the importance...

  • Moving forward with circulating tumor cells and lung cancer. Hiltermann, T.Jeroen.N.; Van Der Wekken, Anthonie J.; M. Groen, Harry J. // Journal of Thoracic Disease;Oct2012, Vol. 4 Issue 5, p440 

    The article discusses the usefulness of circulating tumor cells (CTCs) in lung cancer. CTC detection and enumeration is a prognostic marker in several tumor types; in non-small cell lung carcinoma (NSCLC), CTCs can be used, however, there is a drawback of in NSCLC that only around 30% of...

  • Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma. Zhang, Chao; Yang, Haitang; Lang, Baoping; Yu, Xiangdong; Xiao, Peng; Zhang, Dian; Fan, Liwen; Zhang, Xiao // Cancer Management & Research;Aug2018, Vol. 10, p2401 

    Background: Primary adenosquamous carcinoma (ASC) of the lung is a rare and aggressive disease. The accurate diagnosis of ASC based on small biopsies is challenging because of the mixed components within the tumor, and this may lead to suboptimal treatment. Furthermore, information about the...

  • EGFR Mutation Testing in Non-Small Cell Lung Cancer. Sriram, Krishna B.; Savarimuthu Francis, Santiyagu M.; Tan, Maxine E.; Bowman, Rayleen V.; Yang, Ian A.; Fong, Kwun M. // Current Respiratory Medicine Reviews;2010, Vol. 6 Issue 4, p310 

    Non-small cell lung cancer [NSCLC] is a major cause of cancer related deaths in the world. In a significant proportion of NSCLC cases, the Epidermal Growth Factor Receptor [EGFR] is over-expressed prompting the development of anti-EGFR therapies. Clinical studies of EGFR tyrosine kinase...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics